BOSTON SCIENTIFIC CORP shareholders Q2 2022

BOSTON SCIENTIFIC CORP's ticker is BSX and the CUSIP is 101137107. A total of 856 filers reported holding BOSTON SCIENTIFIC CORP in Q2 2022. The put-call ratio across all filers is 0.85 and the average weighting 0.3%.

BOSTON SCIENTIFIC CORP shareholders Q2 2022
NameSharesValueWeighting ↓
Sendero Wealth Management, LLC 54,904$2,046,0001.96%
HOMESTEAD ADVISERS CORP 1,821,526$67,888,0001.92%
OSTERWEIS CAPITAL MANAGEMENT INC 679,675$25,332,0001.90%
HealthCor Management, L.P. 500,000$18,635,0001.87%
TANDEM CAPITAL MANAGEMENT CORP /ADV 62,254$2,320,0001.86%
PREMIER ASSET MANAGEMENT LLC 55,805$2,291,0001.85%
Nexus Investment Management ULC 404,134$15,062,0001.73%
PRIO WEALTH LIMITED PARTNERSHIP 1,143,668$42,624,5061.70%
ANCHOR CAPITAL ADVISORS LLC 1,505,958$56,127,0001.42%
Ellsworth Advisors, LLC 93,490$3,484,0001.41%
Community Capital Management, LLC 31,000$1,155,0001.40%
PARNASSUS INVESTMENTS, LLC 15,691,959$584,839,0001.40%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 20,806,144$775,455,0001.40%
NBW CAPITAL LLC 133,785$4,986,0001.37%
ZWJ INVESTMENT COUNSEL INC 627,458$23,385,0001.37%
NICOLA WEALTH MANAGEMENT LTD. 383,400$14,289,0001.36%
OMERS ADMINISTRATION Corp 2,486,460$92,670,0001.34%
RBA Wealth Management, LLC 63,687$2,374,0001.32%
Woodline Partners LP 2,261,992$84,304,0001.30%
ATALANTA SOSNOFF CAPITAL, LLC 1,126,913$42,000,0001.27%
About BOSTON SCIENTIFIC CORP

Boston Scientific Corp is a leading medical device company that specializes in developing innovative medical technologies. The company has a strong presence in the global market and is known for its high-quality products and services. Boston Scientific Corp has a diverse portfolio of products that cater to a wide range of medical needs, including cardiovascular, urology, and endoscopy.

The company has a strong leadership team, with Michael F. Mahoney serving as the CEO and Chairman of the Board. Under his leadership, Boston Scientific Corp has continued to grow and expand its operations. The company has a strong focus on research and development, with a significant portion of its revenue being invested in this area.

Boston Scientific Corp has also been actively involved in mergers and acquisitions, which has helped the company to expand its product portfolio and enter new markets. In 2018, the company acquired NxThera, a medical device company that specializes in treating prostate conditions. This acquisition has helped Boston Scientific Corp to strengthen its position in the urology market.

Overall, Boston Scientific Corp is a strong and reliable company that is well-positioned for future growth. With a strong leadership team, a diverse portfolio of products, and a focus on research and development, the company is poised to continue its success in the global medical device market.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BOSTON SCIENTIFIC CORP's shareholders in Q2 2022. To view BOSTON SCIENTIFIC CORP's shareholder history, click here.